Literature DB >> 18784738

Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells.

M C Minnema, M S van der Veer, T Aarts, M Emmelot, T Mutis, H M Lokhorst.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18784738     DOI： 10.1038/leu.2008.247

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  35 in total

1.  Lenalidomide enhances anti-myeloma cellular immunity.

Authors:  Katarina Luptakova; Jacalyn Rosenblatt; Brett Glotzbecker; Heidi Mills; Dina Stroopinsky; Turner Kufe; Baldev Vasir; Jon Arnason; Dimitri Tzachanis; Jeffrey I Zwicker; Robin M Joyce; James D Levine; Kenneth C Anderson; Donald Kufe; David Avigan
Journal:  Cancer Immunol Immunother       Date:  2012-06-24       Impact factor: 6.968

2.  Bortezomib for post-allogeneic hematopoietic stem transplantation relapse and GVHD in multiple myeloma: a single institute experience.

Authors:  Junya Kuroda; Tsutomu Kobayashi; Yasuhiko Tsutsumi; Mio Yamamoto; Muneo Ohshiro; Nana Sasaki; Yuji Shimura; Shinsuke Mizutani; Hisao Nagoshi; Miki Kiyota; Ryuko Nakayama; Hitoji Uchiyama; Yosuke Matsumoto; Shigeo Horiike; Chihiro Shimazaki; Masafumi Taniwaki
Journal:  Int J Hematol       Date:  2010-10-27       Impact factor: 2.490

Review 3.  Minimal residual disease following allogeneic hematopoietic stem cell transplantation.

Authors:  Nicolaus Kröger; Koichi Miyamura; Michael R Bishop
Journal:  Biol Blood Marrow Transplant       Date:  2010-11-01       Impact factor: 5.742

Review 4.  Novel and emerging targeted-based cancer therapy agents and methods.

Authors:  Mohammad Hojjat-Farsangi
Journal:  Tumour Biol       Date:  2015-02-09

5.  Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patients.

Authors:  Akihiro Kitadate; Hiroki Kobayashi; Yoshiaki Abe; Kentaro Narita; Daisuke Miura; Masami Takeuchi; Kosei Matsue
Journal:  Haematologica       Date:  2019-04-19       Impact factor: 9.941

6.  Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial.

Authors:  Katja Sockel; Martin Bornhaeuser; Eva Mischak-Weissinger; Rudolf Trenschel; Martin Wermke; Christian Unzicker; Guido Kobbe; Jürgen Finke; Ulrich Germing; Brigitte Mohr; Jochen Greiner; Dietrich Beelen; Christian Thiede; Gerhard Ehninger; Uwe Platzbecker
Journal:  Haematologica       Date:  2012-09       Impact factor: 9.941

7.  Lenalidomide in the treatment of plasma cell dyscrasia: state of the art and perspectives.

Authors:  Antonio Palumbo; Federica Cavallo
Journal:  Haematologica       Date:  2013-05       Impact factor: 9.941

8.  A prospective study of lenalidomide monotherapy for relapse after Allo-SCT for multiple myeloma.

Authors:  W I Bensinger; D J Green; N Burwick; P S Becker
Journal:  Bone Marrow Transplant       Date:  2014-01-13       Impact factor: 5.483

Review 9.  In search of the optimal platform for Post-Allogeneic SCT immunotherapy in relapsed multiple myeloma: a systematic review.

Authors:  R Oostvogels; S M Uniken Venema; M de Witte; R Raymakers; J Kuball; N Kröger; M C Minnema
Journal:  Bone Marrow Transplant       Date:  2017-07-10       Impact factor: 5.483

10.  Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro.

Authors:  Isabelle Krämer; Melanie Engelhardt; Sabrina Fichtner; Brigitte Neuber; Sergej Medenhoff; Uta Bertsch; Jens Hillengass; Marc-Steffen Raab; Dirk Hose; Anthony D Ho; Hartmut Goldschmidt; Michael Hundemer
Journal:  Oncoimmunology       Date:  2016-02-18       Impact factor: 8.110
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.